Signs supply agreement with Washington University in the United States

Neurofit, an artificial intelligence (AI) company specializing in the diagnosis and treatment of brain diseases, announced on the 10th that it has signed a supply agreement with Washington University in the United States for its brain imaging analysis solutions “Neurofit Aqua” and “Neurofit Scale PET.”

Neurofit Makes First U.S. Supply of Brain Imaging Analysis Solutions View original image

This agreement marks the company’s first achievement in the U.S. market since the establishment of its U.S. subsidiary in October last year and the hiring of a head of Americas business in December. Leveraging this supply deal, Neurofit plans to build references mainly among research institutions in the United States and expand product supply.


Neurofit Aqua is software that quantitatively analyzes brain atrophy, white matter degeneration, and other factors based on brain magnetic resonance imaging (MRI) scans. It quantifies structural changes observed in neurodegenerative diseases such as Alzheimer’s disease and vascular dementia and provides the results of the analysis.


Neurofit Scale PET is a quantitative analysis solution for positron emission tomography (PET) imaging. It automatically calculates SUVR (standardized uptake value ratio) values for major brain imaging biomarkers, including amyloid beta and tau proteins associated with Alzheimer’s disease, as well as FDG and dopamine.



Neurofit Co-CEO Bin Joonkil said, “By supplying our solutions to a U.S. research institution, we have laid the groundwork for expanding in the local market,” adding, “We will continue to broaden our distribution channels within the United States.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing